Analysts Remain Bullish on Gilead (GILD) as Antiviral Franchise Solid

October 24, 2012 11:14 AM

Following the company’s strong earnings report, Needham & Company reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) and raised ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found